Evaluation of the clinical efficacy of anagliptin in type 2 diabetic patients with diabetic nephropathy.
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
Price : $35 *
At a glance
- Drugs Anagliptin (Primary)
- Indications Diabetic neuropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 27 Dec 2016 Status changed from active, no longer recruiting to completed.
- 19 Jan 2014 New trial record